Quick Answer
Perspective Therapeutics, Inc. reported Total Revenue of $5.92 million for fiscal year 2018.
Perspective Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$103.12M -30.1% |
-$79.28M -70.5% |
-$46.51M -539.5% |
-$7.27M -114.7% |
-$3.39M +1.7% |
-$3.45M +33.0% |
| Diluted EPS | -$1.40 -13.8% |
-$1.23 +29.3% |
-$1.74 | — | — | — |
| Total Assets | $266.97M -21.7% |
$341.10M +248.4% |
$97.89M +51.9% |
$64.44M -8.5% |
$70.42M +709.5% |
$8.70M -7.7% |
| Cash and Equivalents | $30.63M -50.3% |
$61.58M +566.6% |
$9.24M -83.5% |
$55.89M -12.4% |
$63.83M +2568.4% |
$2.39M -55.1% |
| Stockholders Equity | $207.03M -28.8% |
$290.67M +286.6% |
$75.18M +22.7% |
$61.28M -9.1% |
$67.41M +1077.8% |
$5.72M -25.5% |
| R&D Expense | $84.22M +102.3% |
$41.64M +95.4% |
$21.31M +2407.2% |
$850.0K -40.4% |
$1.43M +26.7% |
$1.13M -23.6% |
| Operating Income | -$113.56M -25.0% |
-$90.89M -122.0% |
-$40.94M -537.8% |
-$6.42M -86.3% |
-$3.45M +0.9% |
-$3.48M +33.8% |
| Gross Profit | — | — | $1.43M | $0.00 -100.0% |
$5.12M -0.1% |
$5.12M +68.2% |
| Shares Outstanding | 74.34M +5.2% |
70.67M +150.8% |
28.18M -80.2% |
142.04M +0.1% |
141.92M +106.0% |
68.90M +2.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $2.19M | +27.3% | +4.6% |
| Net Income | September 30, 2025 | -$25.97M | -71.7% | -20.9% |
| Diluted EPS | September 30, 2025 | -$0.35 | -66.7% | -20.7% |
| Total Assets | September 30, 2025 | $294.82M | -24.6% | -5.1% |
| Cash and Equivalents | September 30, 2025 | $26.76M | -88.2% | -7.2% |
| Stockholders Equity | September 30, 2025 | $242.22M | -26.3% | -8.8% |
| R&D Expense | September 30, 2025 | $20.34M | +69.1% | +22.4% |
| Operating Income | September 30, 2025 | -$27.86M | -49.5% | -15.9% |
| Gross Profit | September 30, 2023 | $738.0K | +78.3% | +197.6% |
| Shares Outstanding | September 30, 2025 | 74.34M | +10.0% | +0.1% |
- Perspective Therapeutics, Inc. reported Total Revenue of $5.92 million for fiscal year 2018.
- Perspective Therapeutics, Inc. showed an increase of +24.4% in Total Revenue compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Net Income of -$103.12 million for fiscal year 2025.
- Perspective Therapeutics, Inc. showed a decrease of -30.1% in Net Income compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Diluted EPS of $1.40 per share (loss) for fiscal year 2025.
- Perspective Therapeutics, Inc. showed a decrease of -13.8% in Diluted EPS compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Total Assets of $266.97 million for fiscal year 2025.
- Perspective Therapeutics, Inc. showed a decrease of -21.7% in Total Assets compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Cash and Equivalents of $30.63 million for fiscal year 2025.
- Perspective Therapeutics, Inc. showed a decrease of -50.3% in Cash and Equivalents compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Stockholders Equity of $207.03 million for fiscal year 2025.
- Perspective Therapeutics, Inc. showed a decrease of -28.8% in Stockholders Equity compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported R&D Expense of $84.22 million for fiscal year 2025.
- Perspective Therapeutics, Inc. showed an increase of +102.3% in R&D Expense compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Operating Income of -$113.56 million for fiscal year 2025.
- Perspective Therapeutics, Inc. showed a decrease of -25.0% in Operating Income compared to the prior fiscal year.
- Perspective Therapeutics, Inc. reported Gross Profit of $1.43 million for fiscal year 2023.
- Perspective Therapeutics, Inc. reported Shares Outstanding of 74.34 million shares for fiscal year 2025.
- Perspective Therapeutics, Inc. showed an increase of +5.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: